Views
1 year ago

gwpfdb7

gwpfdb7

Research and Clinical

Research and Clinical Trials Scientific and technological advances and growing understanding of the underlying mechanisms of disease are fueling the development of new treatments and cures for patients. At the same time, the costs, time, and complexities of biopharmaceutical research have also increased, introducing additional challenges in the research and development (R&D) process. The drug development process begins with the screening of an enormous number of potential medicines with some companies screening compound libraries numbering in the millions. From the time a potentially promising candidate medicine is identified and optimized, on average it takes 10 to 15 years for a medicine to make its way through the entire R&D process to US Food and Drug Administration (FDA) approval. And only 12% of investigative medicines entering clinical trials are ultimately approved by the FDA. The average cost to develop a new medicine is estimated at $2.6 billion dollars, including the cost of failures. Evidence suggests these costs 46 Research and Clinical Trials

are on the rise and even higher when accounting for the cost of research that continues after a medicine has been approved. In fact, the cost of development has more than doubled over the last decade (see Figure 15). 1 R&D spending by US businesses. 3 Today, there are more than 7,000 medicines in development globally, with the potential to address serious unmet needs of patients with a variety of complex and challenging diseases. 4 In light of these challenges, the nation’s innovative biopharmaceutical research companies remain committed to bringing new and important treatment options to patients and are working to introduce new efficiencies in the R&D process. PhRMA members alone invested an estimated $58.8 billion in R&D in 2015 and have invested more than half a trillion since 2000. 2 One of the nation’s most R&D intensive enterprises, the biopharmaceutical sector represents the single largest share of business R&D, accounting for approximately 17% of all OVERVIEW OF THE R&D PROCESS Although millions of potential drug candidates may be screened and assessed early in the R&D process, many compounds ultimately fail to make it through the R&D pipeline. Candidate medicines must navigate a lengthy, complicated, multistep process before being approved by the FDA and delivered to patients. And the journey does not end with FDA approval; ongoing research and data collection, as the medicine is used in a clinical setting and examined in any required post-approval studies, will continue to provide FIGURE 15: The Costs of Drug Development Have More Than Doubled Over the Past Decade $2.6B KEY DRIVERS of increasing R&D costs: • increased clinical trial complexity Average Cost to Develop One New Approved Drug—Including the Cost of Failures (in Constant 2013 Dollars) • larger clinical trial sizes • greater focus on targeting $1.0B chronic and degenerative diseases • higher failure rates for drugs tested in earlier phase clinical $179M $413M studies 1970s 1980s 1990s–early 2000s* 2000s–early 2010s *Previous research by same author estimated average R&D costs in the early 2000s at $1.2 billion in constant 2000 dollars (see DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? Managerial and Decision Economics. 2007;28: 469-479). That estimate is based on the same underlying survey as the author's estimates for the 1990s to early 2000s reported here ($800 million in constant 2000 dollars), but updated for changes in the cost of capital. Source: DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Economics. 2016;47:20-33. Research and Clinical Trials 47

PHOTO TO BE INSERTED
Making a Killing AMENDED - Animal Aid
I've Got Nothing to Lose by Trying It - Sense About Science
I've Got Nothing to Lose by Trying It - Sense About Science
WHO-Medicines-Report-FINAL2015
you can read it here. - Ratbags
RxD-Magazine-FINAL-Online
Life Science Newsletter No. 3 2010 - Plesner
Fiction?
WHO-Medicines-Report-FINAL2015
Fiction?
220-Dictionary of Pharmaceutical Medicine, 2nd Edition-Gerhard Nahler Annette Mollet-3211898352-S